Literature DB >> 10217604

Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA.

P Lundholm1, Y Asakura, J Hinkula, E Lucht, B Wahren.   

Abstract

Novel ways of delivering plasmid DNA to elicit humoral IgA, IgG and cell-mediated immune responses in mice were investigated. Intraoral administration of DNA in the cheek, using a jet immunization technique, elicited the highest IgA mucosal responses. Intranasal immunization gave strong mucosal IgA responses and persistent systemic IgG. Immunoglobulin isotype analysis revealed an IgG1 profile for intramuscular tongue and gene gun immunizations and an IgG2a profile following oral jet injection and intranasal application. The route of delivery was of importance for the characteristics and quality of the mucosal immune response following DNA immunization. For DNA vaccine delivery, the intraoral jet injection technique has the advantages of being a simple and rapid way of administering the DNA in solution and of provoking specific mucosal IgA when administered in the mucosal associated lymphoid tissue.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217604     DOI: 10.1016/s0264-410x(98)00404-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 4.  Microneedle-Mediated Vaccine Delivery to the Oral Mucosa.

Authors:  Rachel L Creighton; Kim A Woodrow
Journal:  Adv Healthc Mater       Date:  2018-12-10       Impact factor: 9.933

5.  Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.

Authors:  Marcio O Lásaro; Wilson B Luiz; Maria E Sbrogio-Almeida; Lucilia S Nishimura; Beatriz E C Guth; Luis C S Ferreira
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Th1-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production.

Authors:  Y Asakura; L J Liu; N Shono; J Hinkula; A Kjerrström; I Aoki; K Okuda; B Wahren; J Fukushima
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

Review 7.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

8.  Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Authors:  Lindvi Gudmundsdotter; Charlotta Nilsson; Andreas Brave; Bo Hejdeman; Patricia Earl; Bernard Moss; Merlin Robb; Josephine Cox; Nelson Michael; Mary Marovich; Gunnel Biberfeld; Eric Sandström; Britta Wahren
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

9.  Low-volume jet injection for intradermal immunization in rabbits.

Authors:  Shuxun Ren; Minglin Li; Joanne M Smith; Louis J DeTolla; Priscilla A Furth
Journal:  BMC Biotechnol       Date:  2002-05-23       Impact factor: 2.563

10.  Mycobacterium tuberculosis infection interferes with HIV vaccination in mice.

Authors:  Lech Ignatowicz; Jolanta Mazurek; Chaniya Leepiyasakulchai; Markus Sköld; Jorma Hinkula; Gunilla Källenius; Andrzej Pawlowski
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.